European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-30

Protease Systems Biology in Tumorigenesis and Neurodegeneration

Cel

Proteolysis affects every protein through limited processing or degradation. Unlike other post−translational modifications, proteolysis is irreversible and occurs intra− and extracellularly. The large number of genetically encoded proteases in man (> 560) illustrates the importance of proteolysis. However, the in vivo substrate profiles of most proteases have remained elusive; presenting a major hurdle to understanding protease function in health and disease.

System−wide identification of protease substrates is now enabled by novel proteomic strategies for the quantitative determination of neo N− and C−termini. In this project, proteolytic events and cleavage products are identified and validated in cellular model systems in order to understand how proteolysis contributes to tumor aggressiveness and neurodegeneration.

In the area of tumor biology, the paracrine loop between cancer and stroma cells is dissected. Both cell types secrete cytokines and cytokine−modifying proteases; thereby potentiating tumor proliferation and invasiveness. Identification of key cleavage events and key proteases in tumor−stroma interaction unravels the role of proteolysis in cellular communication. In addition, the substrate profile of the stroma−specific, cell−surface protease “Fibroblast activation protein” is determined.

In the area of neurodegeneration, this project identifies and validates substrates of the orphan, neuroprotective protease DJ−1. Mutants of DJ−1 are associated with early−onset Parkinsonism. In addition a novel dual−label approach for the monitoring protein−specific degradation rates on a proteome−wide scale is established. This unique strategy examines the relation between a–synuclein aggregation (a hallmark of Parkinson’s disease) and impaired proteome turnover.

The combination of novel proteomic techniques with state−of−the−art cell biological approaches is uniquely suited to determine how proteases control cellular fate in tumorigenesis and neurodegeneration.

Zaproszenie do składania wniosków

ERC-2011-StG_20101109
Zobacz inne projekty w ramach tego zaproszenia

System finansowania

ERC-SG - ERC Starting Grant

Instytucja przyjmująca

UNIVERSITAETSKLINIKUM FREIBURG
Wkład UE
€ 1 499 760,00
Adres
HUGSTETTER STRASSE 49
79106 Freiburg
Niemcy

Zobacz na mapie

Region
Baden-Württemberg Freiburg Freiburg im Breisgau, Stadtkreis
Rodzaj działalności
Higher or Secondary Education Establishments
Kierownik naukowy
Oliver Schilling (Dr.)
Kontakt administracyjny
Jürgen Dreyer (Mr.)
Linki
Koszt całkowity
Brak danych

Beneficjenci (1)